Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) saw its stock price plummet 8.59% in after-hours trading on Tuesday, reversing course from its earlier surge. The sharp decline came following two significant announcements from the company that raised concerns about potential share dilution and changes in its capital-raising strategy.

Late Tuesday, Olema announced plans for a public offering of common stock and pre-funded warrants. This move, which could increase the number of outstanding shares, typically leads to dilution of existing shareholders' stakes. Adding to investor worries, the company also revealed the termination of its At-The-Market (ATM) Prospectus for common stock dated January 6, 2025, signaling a shift in its approach to raising capital.

The after-hours plunge is particularly notable given Olema's stellar performance earlier in the day, when its shares soared over 140% following positive Phase 3 results from Roche's breast cancer drug trial. The volatility was further intensified by notorious "Pharma Bro" Martin Shkreli's public declaration of a short position in Olema stock, citing skepticism about the company's valuation in light of competition in the Selective Estrogen Receptor Degrader (SERD) market. As the biotech sector continues to show signs of recovery, Olema's stock movement highlights the often unpredictable nature of pharmaceutical investments, especially in reaction to financing decisions and market dynamics.